Skip to main contentAI and Advanced
/
CORONA · NSEBSE SENSEX76,132.81-0.50%BSE |
NIFTY 5023,779.15-0.50%NSE |
NIFTY BANK57,088.3-0.49%NSE |
NIFTY IT29,995.2-2.28%NSE |
NIFTY AUTO27,698.75-0.04%NSE |
NIFTY FMCG45,592.15-0.66%NSE |
NIFTY PHARMA26,675.5+0.75%NSE |
NIFTY 50023,156.2-0.42%NSE |
CO
NSE · Equity shares · Biotechnology & Drugs-23.10 · -1.10%
Corona Remedies CORONA
NSE:INR 2,077
BSE:INR 2,080.8
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for CORONA
Analysis, reports, chat and Advanced access use the same ShareKeyX account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 2,100.1
Day rangeINR 2,056.7 — INR 2,108.6
52-week rangeINR 1,336.6 — INR 2,270.1
Volume8,419
Market cap12,527.15
P/E60.46
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)1,403.18
Net Income (INR Cr)185.12
P/E Ratio60.46
EPS32.74
Research path: Interpret Corona Remedies's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
CORONACorona Remedies1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 1,205.14 | 929.86 | 830.58 |
| Accumulated Depreciation Total | -68.2 | -52.98 | -41.21 |
| Other Liabilities Total | 66.07 | 38.61 | 32.04 |
| Accrued Expenses | 0.05 | 0.47 | 0 |
| Long Term Debt | 0 | 16 | 67 |
| Common Stock Total | 61.16 | 61.16 | 61.16 |
| Other Current Assets Total | 42.66 | 8.33 | 11.62 |
| Prepaid Expenses | 5.71 | 11.78 | 10.59 |
| Total Assets | 1,205.14 | 929.86 | 830.58 |
| Current Portof LT Debt/Capital Leases | 19.11 | 49.21 | 69.31 |
| Cash | 1.83 | 3.22 | 3.16 |
| Total Equity | 746.86 | 606.34 | 480.41 |
| Long Term Investments | 154.99 | 27.21 | 28.73 |
| Retained Earnings(Accumulated Deficit) | 685.7 | 545.18 | 419.25 |
| Total Common Shares Outstanding | 6.12 | 6.12 | 6.12 |
| Property/Plant/Equipment Total-Gross | 502.46 | 437.66 | 352.81 |
| Tangible Book Valueper Share Common Eq | 79.14 | 71.16 | 47.04 |
| Total Liabilities | 458.28 | 323.52 | 350.17 |
| Total Debt | 164.85 | 86.23 | 158.95 |
| Short Term Investments | 27 | 64.82 | 65.89 |
| Cashand Short Term Investments | 28.83 | 68.04 | 69.05 |
| Total Receivables Net | 146.11 | 121.24 | 100.31 |
| Notes Payable/Short Term Debt | 126.86 | 0 | 0 |
| Deferred Income Tax | 12.16 | 8.3 | 4.29 |
| Accounts Receivable-Trade Net | 145.55 | 118.29 | 99.93 |
| Property/Plant/Equipment Total-Net | 434.26 | 384.68 | 311.59 |
| Total Current Liabilities | 361.17 | 239.59 | 224.19 |
| Total Inventory | 125 | 129.48 | 98.35 |
| Accounts Payable | 147.07 | 143.52 | 114.3 |
| Other Currentliabilities Total | 68.08 | 46.39 | 40.59 |
| Total Long Term Debt | 18.88 | 37.02 | 89.65 |
| Intangibles Net | 262.83 | 171.15 | 192.69 |
| Other Long Term Assets Total | 1.17 | 0.04 | 0.15 |
| Note Receivable-Long Term | 3.58 | 7.91 | 7.5 |
| Total Current Assets | 348.31 | 338.87 | 289.92 |
| Capital Lease Obligations | 18.88 | 21.02 | 22.65 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio2.17
Price to Sale Ratio8.93
Margins
Operating Margin 12m17.29
Net Profit Margin 12m13.46
Yield
Dividend Yield %0.48
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskBalanced risk
Board Risk34.33
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 69.00%
- FII
- 3.63%
- MF
- 12.50%
- Other
- 14.87%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
CORONA Remedies promoter confirms no encumbrance on shares in FY26 - scanx.tradeMarket news · 4 Jun 2026, 9:32 pm
CORONA Remedies promoter confirms no encumbrance on shares in FY26 scanx.trade
Corona Remedies Ltd Technical Momentum Shifts Amid Mixed Market Signals - Markets MojoMarket news · 3 Jun 2026, 10:38 am
Corona Remedies Ltd Technical Momentum Shifts Amid Mixed Market Signals Markets Mojo
Corona Remedies to hold investor meetings in Singapore on June 8 - scanx.tradeMarket news · 3 Jun 2026, 9:33 am
Corona Remedies to hold investor meetings in Singapore on June 8 scanx.trade
Corona Remedies Ltd Downgraded to Sell Amid Technical and Financial Concerns - Markets MojoMarket news · 3 Jun 2026, 9:16 am
Corona Remedies Ltd Downgraded to Sell Amid Technical and Financial Concerns Markets Mojo
Corona Remedies Ltd is Rated Hold - Markets MojoMarket news · 3 Jun 2026, 8:15 am
Corona Remedies Ltd is Rated Hold Markets Mojo
CORONA Remedies receives EU-GMP certification for hormone facility - Indian Pharma PostMarket news · 2 Jun 2026, 7:08 am
CORONA Remedies receives EU-GMP certification for hormone facility Indian Pharma Post
Corporate actions
Events
- board MeetingsQuarterly Results
- dividendRs.10.0000 per share(100%)Final Dividend
- board MeetingsAudited Results & Final Dividend
- board MeetingsQuarterly Results
- board MeetingsInter-alia, to consider and approve the financial results for the period ended September 30, 2025
ShareKeyX Community
Discussion and sentiment for Corona Remedies
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and ShareKeyX AI.
Checking your ShareKeyX account…
Company profile
Business information
What the company does
Corona Remedies Limited is an India-based pharmaceutical formulation company. The Company is engaged in developing, manufacturing and marketing products in women’s healthcare, cardio-diabetes, pain management, urology and other/multispecialty pharmaceuticals (comprising vitamins/minerals/nutrition (VMN), gastrointestinal and respiratory). Its diverse product portfolio comprises approximately 67 brands catering to a range of therapeutic areas. It has four dosage forms in pain management formulations, which it offers in the form of tablets, capsules, sprays and injections for treatments associated with musculoskeletal spasms and diabetes. It holds brands across the women’s healthcare lifecycle, from adolescence to infertility, pregnancy, post-pregnancy and pre- and post-menopause categories. Its brands include such as C-HOP; Trazer; COR; Cortel; Rosuless; Bisobis; Sitabite; Dapabite; Fur; Voglibite; Angiwell; Stimucor; Argihope, and others.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- CORONA
- BSE Code
- 544644
Questions
Stock FAQ
What is the symbol and ISIN of Corona Remedies?
Corona Remedies has the symbol CORONA and ISIN - INE02ZQ01018.
What is the current price of Corona Remedies?
Corona Remedies is currently trading at INR 2,077.00.
What are the year high and year low of Corona Remedies?
Corona Remedies has a year high of INR 2,270.10 and a year low of INR 1,336.60.
What is the market capitalization of Corona Remedies?
Corona Remedies has a market capitalization of INR 12,527.15 crore.
What is the P/E ratio of Corona Remedies?
Corona Remedies has a P/E ratio of 60.46.
What is the dividend yield of Corona Remedies?
Corona Remedies has a dividend yield of 0.48%.
How is the financial performance of Corona Remedies based on revenue, net income, and EPS?
Corona Remedies has revenue of INR 1,403.18 crore, net income of INR 185.12 crore, and EPS of INR 34.87.
What is the book value of Corona Remedies?
Corona Remedies has a book value of NA.
What is the debt-to-equity ratio of Corona Remedies?
Corona Remedies has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Corona Remedies?
Corona Remedies has a price-to-book ratio of NA and a price-to-sales ratio of 8.93.
Corporate-action adjustment is provider-defined. ShareKeyX research and computed indicators are not investment advice.